Newsroom
Sorted by: Latest
-
Samenvatting: Baszucki Group financiert klinische studie van Universiteit van Oxford naar ketogene therapie voor vroege psychose
SAN MATEO, Calif.--(BUSINESS WIRE)--De Baszucki Group heeft vandaag een subsidie van £ 1,17 miljoen pond aangekondigd ter ondersteuning van een gerandomiseerde, gecontroleerde studie aan de Universiteit van Oxford. Deze studie onderzoekt de haalbaarheid, veiligheid en werkzaamheid van een ketogeen dieet voor patiënten met een klinisch hoog risico op psychose (CHR-P). Onderzoekers zullen de effectiviteit van deze voedingstherapie testen op de verbetering van de mentale en fysieke gezondheid van...
-
Riassunto: Baszucki Group finanzia lo studio clinico dell'Università di Oxford sulla terapia chetogenica per l'esordio psicotico precoce
SAN MATEO, California--(BUSINESS WIRE)--Baszucki Group ha annunciato oggi un finanziamento di 1,17 milioni di sterline a sostegno di uno studio clinico controllato randomizzato presso l'Università di Oxford per la valutazione della fattibilità, sicurezza ed efficacia di una dieta chetogenica per pazienti a elevato rischio clinico di psicosi (CHR-P). I ricercatori sottoporranno a test la capacità di questa terapia nutrizionale di migliorare la salute mentale e fisica dei pazienti. Questo progett...
-
HealthNet and AndHealth Celebrate Pharmacy Ribbon Cutting at Barrington Location, Improving Medication Access Across Central Indiana
INDIANAPOLIS, Ind.--(BUSINESS WIRE)--HealthNet and AndHealth celebrated the ribbon cutting of the newly opened HealthNet Pharmacy this week, marking a major investment in affordable pharmacy access, integrated specialty care, and medication support services for patients across Central Indiana. The new pharmacy is located inside HealthNet Specialty Care at Barrington Health & Dental Center on Indianapolis’ east side and expands the organization’s ability to serve patients facing rising barri...
-
Die Baszucki Group finanziert eine klinische Studie der Universität Oxford zur ketogenen Therapie bei frühzeitiger Psychose
SAN MATEO, Kalifornien--(BUSINESS WIRE)--Die Baszucki Group gab heute bekannt, dass sie eine Förderung in Höhe von 1,17 Millionen Pfund für eine randomisierte kontrollierte Studie an der Universität Oxford bereitstellt, in der die Durchführbarkeit, Sicherheit und Wirksamkeit einer ketogenen Diät bei Patienten mit einem hohen klinischen Psychoserisiko (CHR-P) untersucht werden soll. Die Forscher werden untersuchen, inwieweit diese Ernährungstherapie die geistige und körperliche Gesundheit der Pa...
-
Baszucki Group finance un essai clinique qui sera mené à l’université d’Oxford sur la thérapie cétogène dans le cadre de la psychose précoce
SAN MATEO, Californie--(BUSINESS WIRE)--Baszucki Group a annoncé aujourd’hui l’octroi d’une subvention de 1,17 million GBP destinée à financer un essai contrôlé randomisé qui sera mené à l’université d’Oxford. Cet essai aura pour but d’évaluer la faisabilité, la sécurité et l’efficacité d’un régime cétogène chez des patients présentant un haut risque clinique de psychose (clinical high risk of psychosis CHR-P). Les chercheurs évalueront la capacité de cette thérapie nutritionnelle à améliorer l...
-
Keller Williams Announces CEO Summit Speakers for Mega Camp 2026
AUSTIN, Texas--(BUSINESS WIRE)--Amy Porterfield, John Lee, Dan Buettner, Shawn Johnson East, and Andrew East to headline KW’s CEO Summit....
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-
Millennium Partners, L.P. UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Millennium International Management LP (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...